Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Eledon Pharmaceuticals, Inc. (NVUS)
|
Add to portfolio |
|
|
|
| Price: |
$4.89
| | Metrics |
| OS: |
23.5
|
M
| |
|
|
| Market cap: |
$115
|
M
| |
|
|
|
Net cash:
|
$40.9
|
M
| |
$1.74
|
per share
|
|
EV:
|
$74.2
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
($1.15)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 39.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 39.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | | | | | | | |
| Research and development | 23.7 | 6.1 | 8.1 | 6.8 | 2.0 | 3.2 | 32.6 | 14.6 |
| General and administrative | 13.1 | 10.1 | 6.1 | 7.2 | 11.1 | 1.9 | 12.6 | 8.9 |
| EBIT | -34.6 | -16.2 | -14.2 | -14.1 | -13.1 | -5.1 | -45.3 | -23.5 |
| EBIT margin | -88.3% | | | | | | | |
| Pre-tax income | -36.9 | -23.2 | -16.0 | -14.1 | -13.1 | -5.7 | -45.1 | -23.3 |
| Income taxes | -2.4 | -0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 6.4% | 1.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -34.5 | -22.8 | -16.0 | -14.1 | -13.1 | -5.7 | -45.1 | -23.3 |
| Net margin | -88.1% | | | | | | | |
| |
| Diluted EPS | ($2.33) | ($15.72) | ($24.42) | ($1.56) | ($2.80) | ($14.77) | ($2.01) | ($3.60) |
| Shares outstanding (diluted) | 14.8 | 1.5 | 0.7 | 9.0 | 4.7 | 0.4 | 22.5 | 6.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|